Providing Answers, Support and Hope in Wisconsin
This is my chapter |
Reset
Kyverna Therapeutics’ application for an Investigational New Drug has been cleared by the Food and Drug Administration. In early 2023, researchers will initiate a Phase 1 clinical trial of the investigational drug KYV-101 for the treatment of lupus kidney disease (lupus nephritis (LN)).
KYV-101 is another version of CAR-T experimental cell therapy that aims to eliminate B cells to reduce inflammation. B-cells are responsible for creating antibodies, including autoantibodies, and are thought to play a role in the development and progression of autoimmune diseases.
Continue to follow the Lupus Foundation of America for updates on KYV-101 and learn more about medications used to treat lupus.
Lupus Foundation of America, Wisconsin Chapter
2600 N Mayfair Road, Suite 320
Milwaukee, WI 53226
414.443.6400
lupuswi@lupuswi.org
There are multiple chapters near you. Select your preferred chapter.
Supporting lupus patients and advocates in Arizona.
Serving the District of Columbia, Maryland, and Northern Virginia.
Serving Kansas, Missouri, and Central & Southern Illinois
Serving north, central and west Texas, including Dallas/Fort Worth, San Antonio, Austin, El Paso, Lubbock, and surrounding areas
Serving Northern Illinois, Indiana, Iowa, Michigan, and Minnesota
Serving Connecticut, Massachusetts, Maine, New Hampshire, northern and central New Jersey, New York, Rhode Island, and Vermont
Serving Pennsylvania, Delaware and Southern New Jersey
Serving Houston, Beaumont, Corpus Christi, Harlingen and surrounding areas in Texas
There are multiple walks near you.
This website uses cookies to ensure you get the best experience. Learn more